Clinical Trials Browser

Phase 1/2 × Neurofibromatosis 2 × 90 days × Clear all

NCT07131722 2026-01-23

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

Phase 1/2 Not yet recruiting

Neurofibromatosis 2